<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02430194</url>
  </required_header>
  <id_info>
    <org_study_id>EIG-300-Amendment 3</org_study_id>
    <nct_id>NCT02430194</nct_id>
  </id_info>
  <brief_title>Lonafarnib With Ritonavir in HDV (LOWR-2)</brief_title>
  <acronym>LOWR-2</acronym>
  <official_title>An Open-label, Dose-ranging, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Lonafarnib With Ritonavir-Boosting in Patients Chronically Infected With Delta Hepatitis (HDV) (LOWR-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eiger BioPharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ankara University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Eiger BioPharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Open-label, Dose-ranging Study to Evaluate the Safety and Efficacy of Lonafarnib With&#xD;
      Ritonavir Boosting in Patients Chronically Infected With Delta Hepatitis (HDV) (LOWR-2).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic delta hepatitis is a serious form of chronic liver disease caused by infection with&#xD;
      the hepatitis D virus (HDV), a small RNA virus that requires farnesylation of its major&#xD;
      structural protein (HDV antigen) for replication. Up to forty-five subjects with chronic&#xD;
      delta hepatitis will be randomized to receive one of nine different doses of lonafarnib.&#xD;
      Dosing will occur over 12-48 weeks, and during that time, evidence of antiviral response will&#xD;
      be assessed by frequent measurements of HDV-RNA. The primary therapeutic endpoint will be an&#xD;
      improvement in quantitative serum HDV RNA levels after treatment with lonafarnib therapy. The&#xD;
      primary safety endpoint will be the ability to tolerate the drug at the prescribed dose for&#xD;
      the treatment duration. Several secondary endpoints will be measured, including side effects,&#xD;
      ALT levels, and symptoms. Therapy will be stopped for intolerance to lonafarnib. This study&#xD;
      is designed as a phase 2a study assessing the safety, tolerance and antiviral activity of&#xD;
      nine dosing combinations of lonafarnib with ritonavir boosting with and without PEG&#xD;
      IFN-alpha.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">June 15, 2017</completion_date>
  <primary_completion_date type="Actual">April 18, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decline of HDV RNA from baseline to end of treatment with lonafarnib and ritonavir</measure>
    <time_frame>12-48 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Chronic Hepatitis D Infection</condition>
  <arm_group>
    <arm_group_label>lonafarnib/ritonavir - I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lonafarnib 100 mg BID + ritonavir 100 mg QD;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lonafarnib/ritonavir - II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lonafarnib 150 mg QD + ritonavir 100 mg QD;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lonafarnib/ritonavir - III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lonafarnib 75 mg BID + ritonavir 100 mg BID; + PEG IFN-a 180 ug QW on Week 12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lonafarnib/ritonavir - IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lonafarnib 50 mg BID + ritonavir 100 mg BID; + PEG IFN-a 180 ug QW on Week 12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lonafarnib/ritonavir - V</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lonafarnib 100 mg BID + ritonavir 50 mg BID;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lonafarnib/ritonavir - VI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lonafarnib 100 mg QD + ritonavir 100 mg QD;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lonafarnib/ritonavir - VII</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lonafarnib 50 mg BID + ritonavir 100 mg BID; + PEG IFN-a 180 ug QW;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lonafarnib/ritonavir/PEG IFN-a - VIII</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lonafarnib 25 mg BID + ritonavir 100 mg BID + PEG IFN-a 180 ug QW;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lonafarnib/ritonavir/PEG IFN-a - IX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lonafarnib 50 mg BID + ritonavir 100 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lonafarnib/ritonavir - X</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lonafarnib 25 mg BID + ritonavir 100 mg BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lonafarnib</intervention_name>
    <description>antiviral farnesyl transferase inhibitor</description>
    <arm_group_label>lonafarnib/ritonavir - I</arm_group_label>
    <arm_group_label>lonafarnib/ritonavir - II</arm_group_label>
    <arm_group_label>lonafarnib/ritonavir - III</arm_group_label>
    <arm_group_label>lonafarnib/ritonavir - IV</arm_group_label>
    <arm_group_label>lonafarnib/ritonavir - V</arm_group_label>
    <arm_group_label>lonafarnib/ritonavir - VI</arm_group_label>
    <arm_group_label>lonafarnib/ritonavir - VII</arm_group_label>
    <arm_group_label>lonafarnib/ritonavir - X</arm_group_label>
    <arm_group_label>lonafarnib/ritonavir/PEG IFN-a - IX</arm_group_label>
    <arm_group_label>lonafarnib/ritonavir/PEG IFN-a - VIII</arm_group_label>
    <other_name>Sarasar, EBP994</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>CYP 3A4 inhibitor, lonafarnib booster</description>
    <arm_group_label>lonafarnib/ritonavir - I</arm_group_label>
    <arm_group_label>lonafarnib/ritonavir - II</arm_group_label>
    <arm_group_label>lonafarnib/ritonavir - III</arm_group_label>
    <arm_group_label>lonafarnib/ritonavir - IV</arm_group_label>
    <arm_group_label>lonafarnib/ritonavir - V</arm_group_label>
    <arm_group_label>lonafarnib/ritonavir - VI</arm_group_label>
    <arm_group_label>lonafarnib/ritonavir - VII</arm_group_label>
    <arm_group_label>lonafarnib/ritonavir - X</arm_group_label>
    <arm_group_label>lonafarnib/ritonavir/PEG IFN-a - IX</arm_group_label>
    <arm_group_label>lonafarnib/ritonavir/PEG IFN-a - VIII</arm_group_label>
    <other_name>Norvir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG IFN-a</intervention_name>
    <description>immunomodulator</description>
    <arm_group_label>lonafarnib/ritonavir - III</arm_group_label>
    <arm_group_label>lonafarnib/ritonavir - IV</arm_group_label>
    <arm_group_label>lonafarnib/ritonavir - VII</arm_group_label>
    <arm_group_label>lonafarnib/ritonavir/PEG IFN-a - VIII</arm_group_label>
    <other_name>Pegasys</other_name>
    <other_name>PEG IFN-alpha</other_name>
    <other_name>Pegylated interferon-alpha-2a</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females, 18 to 65 years of age who are diagnosed with HDV by PCR&#xD;
&#xD;
          -  Chronic hepatitis D infection, genotype 1, documented by a positive anti-HDV Ab test&#xD;
             at least of 6 months duration and detectable HDV RNA by PCR within 3 months to study&#xD;
             entry&#xD;
&#xD;
          -  Liver biopsy within the last two years (biopsy can be done at the Screening Visit)&#xD;
&#xD;
          -  Positive viral load of &gt;100,000 copies/mL as measured by quantitative PCR&#xD;
&#xD;
          -  Electrocardiogram (ECG) shows no acute ischemia or clinically significant abnormality&#xD;
             and a QT/QTc interval &lt;450 milliseconds - using Bazett's correction&#xD;
&#xD;
          -  Females of childbearing potential (intact uterus and within 1 year since the last&#xD;
             menstrual period) should be non-lactating and have a negative serum pregnancy test. In&#xD;
             addition, these subjects should agree to use one of the following acceptable birth&#xD;
             control methods throughout the study:&#xD;
&#xD;
               1. abstinence&#xD;
&#xD;
               2. surgical sterilization (bilateral tubal ligation, hysterectomy, bilateral&#xD;
                  oophorectomy) six months minimum&#xD;
&#xD;
               3. IUD in place for at least six months&#xD;
&#xD;
               4. barrier methods (condom or diaphragm) with spermicide&#xD;
&#xD;
               5. surgical sterilization of the partner (vasectomy for six months)&#xD;
&#xD;
               6. hormonal contraceptives for at least three months prior to the first dose of&#xD;
                  study drug&#xD;
&#xD;
          -  Willing and able to comply with study procedures and provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in a clinical trial with or use of any investigational agent within 30&#xD;
             days of Study Visit 1&#xD;
&#xD;
          -  Patients co-infected with HIV&#xD;
&#xD;
          -  Patients with screening tests positive for HCV, or anti-HIV Ab&#xD;
&#xD;
          -  History of decompensated cirrhosis within the past year&#xD;
&#xD;
          -  Active jaundice defined by total bilirubin &gt; 2.0 excluding Gilbert's disease&#xD;
&#xD;
          -  INR ≥ 1.5&#xD;
&#xD;
          -  Eating disorder or alcohol abuse within the past 2 years, excessive alcohol intake (&gt;&#xD;
             20 g per day for females (1.5 standard alcohol drinks) or &gt; 30 g per day for males&#xD;
             (2.0 standard alcohol drinks) (a standard drink contains 14 g of alcohol: 12 oz of&#xD;
             beer, 5 oz of wine or 1.5 oz of spirits) (1.0 fluid oz (US) = 29.57 mL)&#xD;
&#xD;
          -  Drug abuse within the last six months with the exception of cannabinoids and their&#xD;
             derivatives&#xD;
&#xD;
          -  Patients with absolute neutrophil count (ANC) &lt; 1500 cells/mm3; platelet count &lt;&#xD;
             100,000 cells/mm3; hemoglobin &lt; 12 g/dL for women and &lt; 13 g/dL for men; abnormal&#xD;
             TSH,T4, or T3 or thyroid function not adequately controlled; or serum creatinine&#xD;
             concentration ≥ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  History or clinical evidence of any of the following:&#xD;
&#xD;
               1. variceal bleeding, ascites, hepatic encephalopathy, CTP score &gt; 6, decompensated&#xD;
                  liver disease or any other form of non-viral hepatitis&#xD;
&#xD;
               2. immunologically mediated disease (e.g., rheumatoid arthritis, inflammatory bowel&#xD;
                  disease, severe psoriasis, systemic lupus erythematosus) requiring more than&#xD;
                  intermittent nonsteroidal anti-inflammatory medications for management or that&#xD;
                  requires frequent or prolonged use of corticosteroids (inhaled asthma medications&#xD;
                  are allowed)&#xD;
&#xD;
               3. any malignancy within 3 years except for basal cell skin cancer&#xD;
&#xD;
               4. significant or unstable cardiac disease (e.g., angina, congestive heart failure,&#xD;
                  uncontrolled hypertension, history of arrhythmia)&#xD;
&#xD;
               5. chronic pulmonary disease (e.g., chronic obstructive pulmonary disease)&#xD;
                  associated with functional impairment&#xD;
&#xD;
               6. severe or uncontrolled psychiatric disease, including severe depression, history&#xD;
                  of suicidal ideation, suicidal attempts or psychosis requiring medication and/or&#xD;
                  hospitalization 2&#xD;
&#xD;
          -  Patients with a body mass index &gt; 30 kg/m2&#xD;
&#xD;
          -  Concomitant drugs known to prolong the QT interval&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cihan Yurdaydin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ankara University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ankara University Medical School</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <link>
    <url>http://eigerbio.com</url>
    <description>Eiger BioPharmaceuticals company website</description>
  </link>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>April 21, 2015</study_first_submitted>
  <study_first_submitted_qc>April 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2015</study_first_posted>
  <last_update_submitted>July 27, 2017</last_update_submitted>
  <last_update_submitted_qc>July 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis D</mesh_term>
    <mesh_term>Hepatitis D, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Lonafarnib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

